This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis (NVS) Stock Moves -0.58%: What You Should Know
by Zacks Equity Research
In the latest trading session, Novartis (NVS) closed at $75.57, marking a -0.58% move from the previous day.
Cytokinetics (CYTK) to Continue ALS Study on Reldesemtiv
by Zacks Equity Research
Cytokinetics (CYTK) plans to continue the COURAGE-ALS study on reldesemtiv in patients with amyotrophic lateral sclerosis following DMC recommendation.
Merck (MRK) Posts Positive Results From PAH Drug Study
by Zacks Equity Research
Merck's (MRK) sotatercept meets primary and secondary endpoints in a phase III study in pulmonary arterial hypertension. The drug was added to MRK's pipeline last year.
Gilead (GILD) Up 2.6% in 3 Months: Will the Momentum Continue?
by Zacks Equity Research
Gilead (GILD) is having a good run despite the volatility on a string of positive updates.
GSK's (GSK) Boostrix Gets FDA Nod for Pertussis in Newborns
by Zacks Equity Research
Following FDA approval, GSK's (GSK) Boostrix is the first vaccine in the United States specifically approved during pregnancy to prevent disease in young infants by vaccinating pregnant women.
BioMarin (BMRN) Starts Restructuring Moves to Increase Efficiency
by Zacks Equity Research
BioMarin (BMRN) intends to reduce the existing workforce by nearly 4%. The company plans to use the savings in costs and redirect them toward its operating expenses.
Lilly's (LLY) Diabetes Drug Gets FDA Fast Track Tag for Obesity
by Zacks Equity Research
Eli Lilly (LLY) receives a fast-track designation from the FDA for tirzepatide to treat obesity in adult patients. The company will begin rolling NDA submission later this year.
The Zacks Analyst Blog Highlights Novartis, Lowe's, The Goldman Sachs, Twitter and Xcel Energy
by Zacks Equity Research
Novartis, Lowe's, The Goldman Sachs, Twitter and Xcel Energy are part of the Zacks top Analyst Blog.
Top Research Reports for Novartis, Lowe's & Goldman Sachs
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Novartis AG (NVS), Lowe's Companies, Inc. (LOW) and The Goldman Sachs Group, Inc. (GS).
GSK's (GSK) PD-1 Inhibitor Drug Meets Lung Cancer Study Goal
by Zacks Equity Research
GSK's (GSK) mid-stage study, evaluating the combination of its cancer drug Jemperli with chemotherapy in non-small cell lung cancer, meets the primary endpoint of objective response rate.
Biohaven (BHVN) Stock Up on Spin-Off Transaction Finalization
by Zacks Equity Research
The newly spun-off Biohaven Ltd. (BHVN) advances a portfolio of non-CGRP pipelines targeting neurological and neuropsychiatric indications.
Can Biogen (BIIB) Navigate Multiple Challenges & Grow Again?
by Zacks Equity Research
Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, we are hopeful that potential new product launches such as lecanemab, zuranolone and additional biosimilars can help revive growth.
NVS vs. RHHBY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVS vs. RHHBY: Which Stock Is the Better Value Option?
Is Novartis (NVS) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Ionis' (IONS) Hypercholesterolemia Drug Not to Enter Phase III
by Zacks Equity Research
Ionis (IONS) posts data from the phase IIb SOLANO study on ION449 for treating hypercholesterolemia. Though the study met the primary endpoint, ION449 will not advance into phase III development.
Novartis (NVS) to Focus on US Markets Backed by 8 Key Drugs
by Zacks Equity Research
Novartis (NVS) unveils a new focused strategy with the spotlight on the US markets driven by eight key brands that are expected to have a multi-billion dollar peak sales potential.
Strength Seen in Lilly (LLY): Can Its 4.9% Jump Turn into More Strength?
by Zacks Equity Research
Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Novartis (NVS) to Appeal to Supreme Court for Gilenya Patent
by Zacks Equity Research
Novartis (NVS) is looking to defend its patents for the multiple sclerosis drug Gilenya and file a petition in the Supreme Court after an unfavorable ruling in the federal court.
Novartis (NVS) Unit Posts Positive Results on Prolia Biosimilar
by Zacks Equity Research
Novartis (NVS) generic unit Sandoz announces that ROSALIA study for its proposed biosimilar of Prolia (denosumab) meets primary endpoints.
Gilead (GILD) Drugs Get Positive CHMP Opinion for Label Expansion
by Zacks Equity Research
Gilead's (GILD) COVID-19 treatment Veklury and CAR T-cell therapy Yescarta get positive CHMP recommendation for additional indications.
The Zacks Analyst Blog Highlights AbbVie, Novartis, Merck and AstraZeneca
by Zacks Equity Research
AbbVie, Novartis, Merck and AstraZeneca are included in this Analyst Blog.
4 Large Drug Stocks to Watch as Fundamentals Stay Strong
by Kinjel Shah
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novartis (NVS), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.
Pharma Stock Roundup: FDA Authorization of Omicron Boosters, SNY's Xenpozyme & More
by Kinjel Shah
FDA authorizes Pfizer (PFE) & Moderna's (MRNA) Omicron-aimed COVID vaccines & Sanofi's (SNY) new drug, Xenpozyme.
Novartis (NVS) Chronic Myeloid Leukemia Drug Approved by EC
by Zacks Equity Research
Novartis (NVS) strengthens its oncology portfolio with EC approval for its chronic myeloid leukemia drug, Scemblix.